Evidence map›Paper›PMID 28656474›Full record

ReviewEuropean journal of pediatrics2017

Dissecting Kawasaki disease: a state-of-the-art review.

S M Dietz, D van Stijn, D Burgner, M Levin, I M Kuipers, B A Hutten, T W Kuijpers

Open access · hybridAbstract readReview
In one paragraph

Review in European journal of pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 7 pooled it
16.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 7 syntheses or guidelines pooled it, 163 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Age-Specific Cardiovascular and Platelet Dynamics in Kawasaki Disease.International journal of general medicine · 2025
    Article
  18. Article
  19. Article
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

S M DietzDepartment of Pediatric Hematology, Immunology and Infectious Diseases, Emma Childrens Hospital, Academic Medical Centre (AMC), Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. s.m.dietz@amc.nl.
D van StijnDepartment of Pediatric Hematology, Immunology and Infectious Diseases, Emma Childrens Hospital, Academic Medical Centre (AMC), Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
D BurgnerMurdoch Childrens Research Institute, Parkville, VIC, Australia.
M LevinPediatric Infectious Diseases Group, Division of Medicine, Imperial College London, London, UK.
I M KuipersDepartment of Pediatric Cardiology, Emma Childrens Hospital, Academic Medical Centre (AMC), Amsterdam, The Netherlands.
B A HuttenDepartment of Clinical Epidemiology, Bioinformatics and Biostatistics, AMC, Amsterdam, The Netherlands.
T W KuijpersDepartment of Pediatric Hematology, Immunology and Infectious Diseases, Emma Childrens Hospital, Academic Medical Centre (AMC), Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Emma Kinderziekenhuis · NLImperial College London · GBNetherlands Bioinformatics Centre · NLUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kawasaki disease (KD) is a pediatric vasculitis with coronary artery aneurysms (CAA) as its main complication. The diagnosis is based on the presence of persistent fever and clinical features including exanthema, lymphadenopathy, conjunctival injection, and changes to the mucosae and extremities. Although the etiology remains unknown, the current consensus is that it is likely caused by an (infectious) trigger initiating an abnormal immune response in genetically predisposed children. Treatment consists of high dose intravenous immunoglobulin (IVIG) and is directed at preventing the development of CAA. Unfortunately, 10-20% of all patients fail to respond to IVIG and these children need additional anti-inflammatory treatment. Coronary artery lesions are diagnosed by echocardiography in the acute and subacute phases. Both absolute arterial diameters and z-scores, adjusted for height and weight, are used as criteria for CAA. Close monitoring of CAA is important as ischemic symptoms or myocardial infarction due to thrombosis or stenosis can occur. These complications are most likely to arise in the largest, so-called giant CAA. Apart from the presence of CAA, it is unclear whether KD causes an increased cardiovascular risk due to the vasculitis itself.

conclusionMany aspects of KD remain unknown, although there is growing knowledge on the etiology, treatment, and development and classification of CAA. Since children with previous KD are entering adulthood, long-term follow-up is increasingly important. What is known: • Kawasaki disease (KD) is a pediatric vasculitis with coronary artery damage as its main complication. • Although KD approaches its 50th birthday since its first description, many aspects of the disease remain poorly understood. What is new: • In recent years, multiple genetic candidate pathways involved in KD have been identified, with recently promising information about the ITPKC pathway. • As increasing numbers of KD patients are reaching adulthood, increasing information is available about the long-term consequences of coronary artery damage and broader cardiovascular risk.

Indexed as

Mucocutaneous Lymph Node SyndromeAnti-Inflammatory AgentsAsiaEchocardiographyEuropeHumansImmunoglobulins, IntravenousImmunologic FactorsQuality of LifeRisk FactorsAnti-Inflammatory AgentsImmunoglobulins, IntravenousImmunologic FactorsCoronary artery aneurysmsGeneticsIntravenous immunoglobulinsKawasaki disease

Identifiers

PMID28656474
PMCPMC5511310
OpenAlexW2731552962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.